Atea Pharmaceuticals (AVIR) Retained Earnings (2020 - 2022)
Historic Retained Earnings for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to -$25.4 million.
- Atea Pharmaceuticals' Retained Earnings rose 5835.16% to -$25.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$25.4 million, marking a year-over-year increase of 5835.16%. This contributed to the annual value of $56.0 million for FY2021, which is 18598.83% up from last year.
- Per Atea Pharmaceuticals' latest filing, its Retained Earnings stood at -$25.4 million for Q3 2022, which was up 5835.16% from -$17.4 million recorded in Q2 2022.
- Over the past 5 years, Atea Pharmaceuticals' Retained Earnings peaked at $56.0 million during Q4 2021, and registered a low of -$85.8 million during Q3 2020.
- For the 3-year period, Atea Pharmaceuticals' Retained Earnings averaged around -$28.0 million, with its median value being -$32.9 million (2021).
- The largest annual percentage gain for Atea Pharmaceuticals' Retained Earnings in the last 5 years was 18598.83% (2021), contrasted with its biggest fall of 2879.88% (2021).
- Atea Pharmaceuticals' Retained Earnings (Quarter) stood at -$65.2 million in 2020, then skyrocketed by 185.99% to $56.0 million in 2021, then plummeted by 145.42% to -$25.4 million in 2022.
- Its Retained Earnings stands at -$25.4 million for Q3 2022, versus -$17.4 million for Q2 2022 and $14.0 million for Q1 2022.